Preparation and evaluations in vitro of oxaliplatin polylactic acid nanoparticles

Figures & data

Figure 1. Oxaliplatin HPLC chromatogram. A: HPLC behavior of OP, B: blank nanoparticle dialysate.

Table I. Results of the recovery tests.

Added (μg/ml)	Found (μg/ml)	Recovery ratio (%)	Mean ( ± s%)	RSD (%)
250	248.64	97.46	97.45 ± 1.27	1.30
	249.24	98.70
	240.46	96.18
500	501.62	100.32	99.50 ± 0.94	0.94
	498.52	99.70
	492.43	98.49
1000	996.34	102.63	101.06 ± 1.64	1.63
	1012.34	101.2
	993.64	99.36

Table II. Factors and levels of orthogonal tests.

Factors	A (%)	B (mg/ml)	C (v/v)	D (w/w)
1	0.25	5	1:3	1:3
2	0.5	10	1:5	1:5
3	1	20	1:8	1:8

Table III. Arrangement and results of orthogonal tests according to L₉(3⁴).

NO	A (%)	B (mg/ml)	C (V/V)	D (W/W)	DL (%)	Particle size (nm)	EE (%)
1	0.25	5	1:3	1:3	5.63	107	16.9
2	0.25	10	1:5	1:5	2.74	85	13.7
3	0.25	20	1:8	1:8	2.52	49.9	20.2
4	0.5	5	1:5	1:8	1.32	48	10.6
5	0.5	10	1:8	1:3	3.30	69.9	9.9
6	0.5	20	1:3	1:5	2.91	120.6	14.5
7	1	5	1:8	1:5	4.05	67.3	20.2
8	1	10	1:3	1:8	3.71	84.2	29.7
9	1	20	1:5	1:3	8.36	349.5	25.1
K1	10.89	11.00	12.26	17.30	K = 34.55225586		Drug loading
K2	7.53	9.75	12.42	9.69
K3	16.13	13.80	9.87	7.56
R	2.86	1.35	0.85	3.25
T1	241.90	220.00	311.80	526.40	T = 981.4		Particle size
T2	238.50	399.10	482.50	272.90
T3	501.00	274.10	187.10	182.10
R	87.50	99.23	98.47	114.77

Figure 2. Shapes of nanoparticles through TEM (× 25,000).

Figure 3. The nanoparticle size distribution.

Table IV. The result of EE, DL and particle size (x ± s, n = 3).

Batch	EE (%)	χ± S (%)	DL (%)	χ± S (%)	Particle size (nm)	χ± S (nm)
1	17.45	17.40 ± 0.47	3.52	3.52 ± 0.07	120.7	120.5 ± 8.7
2	17.83		3.58		112.5
3	16.92		3.45		128.5